Physician profile
Liam Gross
NPI 1578862769
$4,012.24
in general payments reported to CMS, 2019-2025
26 companies · $1,545 in 2025
The $1,545 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2022: $208 · 2023: $1,361 · 2024: $753 · 2025: $1,545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,580 · Education: $78.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,580.02 |
| Education | $78.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $718.40 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $611.77 | 2023-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $562.12 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $400.83 | 2022-2025 | Dupixent |
| Amgen INC. | $241.87 | 2022-2025 | Tezspire |
| Insmed, INC. | $223.73 | 2023-2025 | Arikayce |
| Inspire Medical Systems, INC. | $186.54 | 2024-2025 | Inspire |
| Inari Medical, INC. | $169.88 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.85 | 2022-2025 | Ofev, Tradjenta, Jardiance |
| Electromed, INC. | $107.49 | 2025 | Smartvest |
| Sanofi-Aventis U.S. LLC | $78.99 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $74.82 | 2022-2025 | Glassia |
| Novartis Pharmaceuticals Corporation | $74.05 | 2019-2023 | |
| Mylan Specialty L.P. | $59.70 | 2023-2024 | Yupelri |
| Mallinckrodt Hospital Products INC. | $49.36 | 2025 | Acthar |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $45.78 | 2023-2025 | Uzedy, Airduo Digihaler |
| Grifols USA, LLC | $42.26 | 2022-2023 | Prolastin-C Liquid |
| Lilly USA, LLC | $41.62 | 2024-2025 | Zepbound, Jardiance |
| Ani Pharmaceuticals, INC. | $38.90 | 2025 | Purified Cortrophin Gel |
| Pfizer INC. | $38.20 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $32.13 | 2023 | Uptravi, Opsumit |
| Bard Access Systems, INC. | $21.38 | 2019 | |
| Baxter Healthcare | $21.35 | 2024 | |
| Merck Sharp & Dohme LLC | $20.44 | 2025 | Keytruda |
| Ultragenyx Pharmaceutical INC. | $18.97 | 2024 | Crysvita |
| Optinose US, INC. | $15.81 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Liam Gross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.